Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Clinical Update

Use of a critical pathway for the management of community-acquired pneumonia: the CAPITAL study

Donald Farquhar
CMAJ September 19, 2000 163 (6) 755;
Donald Farquhar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Marrie T, Lau C, Wheeler S, Wong C, Vandervoort M, Feagan B. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. Community-Acquired Pneumonia Intervention Trial. JAMA 2000;283:749-55.

Background

Many hospitals in Canada and the United States have implemented critical pathways (CPs) to reduce variation and control costs in the management of several common conditions. These pathways combine evidence-based practice parameters with guidelines for the timely completion of specific steps in the process of care. Whether they achieve their goals without compromising quality of care has not been rigorously studied as yet.1,2

Question

Does the use of a CP for the management of community-acquired pneumonia reduce hospital resource consumption without adversely affecting clinical outcomes?

Design

This study randomly allocated 20 Canadian hospitals to the use of either a CP or conventional management for the treatment of community-acquired pneumonia.3 Key components of the pathway included a risk-stratification tool (pneumonia severity index) to guide decision-making about hospital admission, a recommendation to use a single, broad- spectrum antimicrobial agent (levofloxacin, 500 mg once daily) and guidelines for the timing of conversion from intravenous to oral antibiotic therapy and hospital discharge. At the CP hospitals, patients were followed daily by a study nurse, who prompted the health care team about the patient‚s progress along the CP by means of a written chart note. Steps were taken to ensure that treating personnel at the hospitals allocated to conventional management had no knowledge of any of the constituent parts of the critical pathway.

The number of bed-days per patient was used as the primary measure of resource consumption. Secondary measures included the proportion of low-risk patients admitted to hospital, the length of stay, the duration of intravenous antibiotic therapy and the proportion of patients receiving a single class of antimicrobial agent. Clinical outcomes included a quality-of-life measure (change, from admission to 6 weeks after completion of treatment, in the physical component summary scale of the Short-Form 36 [SF-36] instrument), as well as rates of pneumonia-related complications, admission to the intensive care unit, hospital readmission and death.

Results

Of the 20 hospitals, 9 treated patients using the CP, 10 used conventional management and 1 withdrew before implementation of the CP. Randomization had been stratified to ensure that each study arm comprised a similar mix of teaching and community hospitals. In total, 1743 eligible patients were enrolled; subjects treated at CP and conventional management hospitals were comparable in age, sex, pneumonia severity index score, baseline SF-36 physical summary scale score, room air oxygen saturation and proportion with chronic lung disease and multilobar pneumonia.

The number of bed-days per patient was significantly lower in the CP group than in the conventional management group (4.4 v. 6.1, p = 0.04). Although admission rates among high-risk patients were comparable in the 2 groups, the rate among low-risk patients was significantly lower in the CP group (31% v. 49%, p = 0.01). Patients in the CP hospitals also had lower median lengths of stay (5.0 v. 6.7 days, p = 0.01), a shorter mean duration of intravenous antibiotic therapy (4.6 v. 6.3 days, p = 0.01) and a higher rate of use of a single class of antimicrobial agent (64% v. 27%, p < 0.001). The change in SF-36 physical summary scale scores and the rates of secondary clinical outcomes did not differ significantly between the 2 groups.

Commentary

This study‚s major strength is its rigorous design. It represents the first large-scale attempt to assess the efficacy of a CP using methodology appropriate to the evaluation of therapeutic interventions (i.e., randomization). The study was not designed to assess the relative contributions of the various constituent parts of the CP or the extent to which success depended on the availability of a designated study nurse to facilitate adherence to the CP.

Implications for practice

The use of a CP for community-acquired pneumonia reduces hospital resource consumption and leads to clinical outcomes comparable to those achieved through conventional management. Further research is needed to determine optimal strategies for implementation of, and adherence to, CPs. —

References

  1. 1.↵
    Pearson SD, Goulart-Fisher D, Lee TH. Critical pathways as a strategy for improving care: problems and potential. Ann Intern Med 1995;123:941-8.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Ellrodt G, Cook DJ, Lee J, Cho M, Hunt D, Weingarten S. Evidence-based disease management. JAMA 1997;278:1687-92.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Marrie T, Lau C, Wheeler S, Wong C, Vandervoort M, Feagan B. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. Community-Acquired Pneumonia Intervention Trial. JAMA 2000;283:749-55.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

CMAJ
Vol. 163, Issue 6
19 Sep 2000
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Use of a critical pathway for the management of community-acquired pneumonia: the CAPITAL study
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Use of a critical pathway for the management of community-acquired pneumonia: the CAPITAL study
Donald Farquhar
CMAJ Sep 2000, 163 (6) 755;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Use of a critical pathway for the management of community-acquired pneumonia: the CAPITAL study
Donald Farquhar
CMAJ Sep 2000, 163 (6) 755;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Early treatment of acute hepatitis C infection may lead to cure
  • Angiotensin-II–receptor blockers and nephropathy in patients with type 2 diabetes
  • Colorectal cancer screening: you can't be positive about a negative result
Show more Clinical Update

Similar Articles

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire